This controlled case study is dedicated to mentalizing as a mechanism of change in the course of a mentalization-based therapy for the treatment of conduct disorder. Following an introduction to conduct, oppositional defiant disorder and the concept of mentalizing, the case study of a 17-year-old male patient is presented. The patient's mentalizing is measured with the Reflective Functioning Scale and assessed prior to and after treatment as well as in therapy sessions at three time points through the course of therapy. Analyses show that the capacity for mentalizing fluctuates noticeably within but also between the coded therapy sessions. During the course of therapy first an increase and then a slight decrease in mentalizing qualities become apparent. The comparison of the pre- and post-measurement shows a slight increase in the patient's mentalizing abilities. Additionally the patient no longer fulfilled the criteria of a conduct disorder. The results are discussed and implications for clinical practice are formulated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.13109/prkk.2019.68.8.760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Testing the Feasibility, Acceptability, and Potential Efficacy of an Innovative Digital Mental Health Care Delivery Model Designed to Increase Access to Care: Open Trial of the Digital Clinic.
JMIR Ment Health
January 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Background: Mental health concerns have become increasingly prevalent; however, care remains inaccessible to many. While digital mental health interventions offer a promising solution, self-help and even coached apps have not fully addressed the challenge. There is now a growing interest in hybrid, or blended, care approaches that use apps as tools to augment, rather than to entirely guide, care.
View Article and Find Full Text PDFA network-based analysis anticipates time to recovery from major depression revealing a plasticity by context interplay.
Transl Psychiatry
January 2025
Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.
Predicting disease trajectories in patients with major depressive disorder (MDD) can allow designing personalized therapeutic strategies. In this study, we aimed to show that measuring patients' plasticity - that is the susceptibility to modify the mental state - identifies at baseline who will recover, anticipating the time to transition to wellbeing. We conducted a secondary analysis in two randomized clinical trials, STAR*D and CO-MED.
View Article and Find Full Text PDFA comprehensive report of the clinical and mutational profiles of 30 Iranian malignant infantile osteopetrosis patients.
Mol Cell Probes
January 2025
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Osteopetrosis is a group of genetically and clinically diverse inherited disorders characterized by an increase in bone density. The main known cause is an abnormality in the development or function of osteoclasts. Hence, the process of bone resorption is impaired, resulting in: 1- a reduction in bone marrow volume and, subsequently, a decrement in the hematopoietic capacity of bone marrow, which leads to anemia and compromised immunological function; 2- improper bone development, which leads to pressure on peripheral nerves, causing auditory, visual, and movement impairments; and 3- disturbance in the formation of bone microstructure that leads to susceptibility to bone fracture.
View Article and Find Full Text PDFPharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFMental Health Assessment of the Population: Study Protocol of the MAP Research Program in Ukraine (MAP-U) and in Zurich (MAP-Z).
Int J Public Health
January 2025
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Objectives: To conduct mental health surveillance in adults in Ukraine and Ukrainian refugees (Canton of Zurich, Switzerland) as an actionable scientific foundation for public mental health and mental healthcare.
Methods: Mental Health Assessment of the Population (MAP) is a research program including prospective, population-based, digital cohort studies focused on mental health monitoring. The study aims to include 17,400 people from the general population of Ukraine, 1,220 Ukrainians with refugee status S residing in the canton of Zurich, and 1,740 people from the Zurich general population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!